- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
_doc_number: he2002_1797
_summary: The Supreme Court has agreed to take up a pharmaceutical industry appeal against the state of Maine's prescription drug program, Maine Rx. The high court today (June 28) granted a Pharmaceutical Research and Manufacturers of America (PhRMA) request for a review of the case. PhRMA believes Maine Rx "would limit Medicaid patients' access to the newest and most effective medications."]
_creation_date: 06/28/2002
_pub_date: 06/28/2002
_priority: 2
_doc_format: as
_subj_cat: drugalert
_name_location:
FOR IMMEDIATE RELEASE
CONTACT: Nancy Thompson or Marty Davis, (202) 434-2560
STATEMENT BY AARP ADVOCACY DIRECTOR CHRIS HANSEN ON THE HOUSE MEDICARE PRESCRIPTION DRUG PLAN
AARP members want a prescription drug benefit signed into law this year. The vote in the U.S. House of Representatives to make a voluntary prescription drug benefit a permanent part of Medicare is a step towards that goal. However, improvements are needed in the funding adequacy, structure, and benefit viability of this plan.
From: "Energy and Commerce Press" <EnergyandCommercePress@mail.house.gov>
To: "Committee on Commerce News" <biotech@docs.house.gov>
Subject: Senior Energy and Commerce Members Send Letter to FDA on ImClone
FOR IMMEDIATE RELEASE:
Friday, June 28, 2002
CONTACT: Ken Johnson or Peter Sheffield
202-225-5735
Senior Energy and Commerce Members Send Letter to FDA on ImClone